Cardiff Oncology, based in San Diego, develops drugs targeting mitosis for cancer treatment, focusing on PLK1 inhibition. Its lead candidate, Onvansertib, is undergoing five clinical trials for various cancers.
CRDF filed a patent for "inhibition of hypoxia signaling pathway by plk1 inhibitor" on Fri, April 5, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
